NCT03497767 - A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

DRUG

Osimertinib

All participants will receive a dose of Osimertinib 80mg once daily

RADIATION

Stereotactic Radiosurgery (SRS)

Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.

Trial Locations (13)

2002

Liverpool Hospital, Sydney

2010

St. Vincents Hospital, Sydney

2145

Westmead Hospital, Sydney

2148

Blacktown Hospital, Sydney

2217

St George Hospital, Sydney

2298

Calvary Mater, Newcastle

3002

Peter MacCallum Cancer Center, Melbourne

3175

Monash Health, Melbourne

4102

Princess Alexandra Hospital, Brisbane

4120

ICON Cancer Centre Greenslopes, Brisbane

119074

National University Hospital, Singapore

Unknown

Royal Adelaide Hospital, Adelaide

Sir Charles Gairdner, Perth

All Listed Sponsors

lead

Trans Tasman Radiation Oncology Group

OTHER